Filters
Documents
Showing 25 of 751 items meeting your criteria.
| Type | Category | Supplier | ||
|---|---|---|---|---|
 | Vaccine, Gene Reporter, Genome Editing & Gene Replacement mRNAs | |||
Documents | RNA | Oz Biosciences | ||
 | HIGH-QUALITY VIRAL ENHANCER | |||
Documents | Transduction | Oz Biosciences | ||
 | Protein Quantification Assays
Enzyme Detection - Reporter Gene Assays
Viability / Apoptosis / Stress Assays | |||
Documents | Cell Based Assays | Oz Biosciences | ||
 | Abnova provides a range of Tumour-Associated Antigens of CAR T Cell Therapy. | |||
Documents | Cancer | Abnova Corporation | ||
 | Abnova provides a range of antibodies for research into TNF-TRAF Signalling. | |||
Documents | Immunology | Abnova Corporation | ||
 | Abnova provides a range of reagents for research into the role of Tumour Necrosis Factor in Amyotrophic Lateral Sclerosis. | |||
Documents | Neuroscience | Abnova Corporation | ||
 | T-cell-dependent antibody response (TDAR) to an antigen is a gold standard in vivo assessment of immunotoxicity at the preclinical stage of drug discovery. Abnova offers a wide variety of ELISA kits for biomarkers used in TDAR assays. | |||
Documents | ELISA | Abnova Corporation | ||
 | Approximately there are 10% of patients with NSCLC in the US and 35% in Asia harboring EGFR mutations. EGFR mutations occur within exons 18–21 encoding a portion of the EGFR kinase domain. These mutations affect the kinase activity of EGFR, leading to downstream pro-survival signaling pathways.
EGFR mutations confer sensitivity of EGFR TKI and as well as are involved in mechanisms of acquired resistance to EGFR TKI therapy. Resistance can occur through secondary resistance mutations (such as T790M) occurring in the ATP-binding domain. | |||
Documents | Cancer | Abnova Corporation | ||
 | Also known as NS7; B-raf; BRAF1; RAFB1; B-RAF1, is a member of the RAF family of serine/threonine protein kinases activating the MAP kinase/ERK-signaling pathway and normally involved in regulating cell differentiation, proliferation, growth, and apoptosis. BRAF V600E mutation drives tumor growth by hyperactivating the extracellular signal regulated kinase (ERK) signaling pathway in the absence of any extracellular stimuli. | |||
Documents | Cancer | Abnova Corporation | ||
 | Exhausted T cells have been identified to accumulate in tumour microenvironment (TME) and fail to eliminate cancer cells. The exhaustion is characterised by the expression of multiple inhibitory molecules, including PD-1 and CTLA4. PD-1/PD-L1 signaling antagonises TCR signaling and induces the transcription of exhaustion-related genes. Both PD-1/PD-L1 and CTLA4 signaling inhibit the pathways that promote cell cycle arrest in T cells. The inhibition of PI3K/Akt/mTOR pathway mediated by PD-1/PD-L1 or CTLA4 also leads to decreases in glycolysis and amino acid metabolism and suppresses mitochondrial biogenesis. These exhaustion-related changes result in dysfunctional T cells, which are obstacles to effective tumour immunotherapy. | |||
Documents | Cancer | Abnova Corporation | ||
 | Neutralising antibodies are able to block the interaction between viruses and host cells, which can potentially stop the infection. Abnova has developed a group of SARS-CoV-2 S monoclonal antibodies, which are neutralising mouse monoclonal antibodies targeting recombinant SARS-CoV-2 spike protein. | |||
Documents | COVID-19 | Abnova Corporation | ||
 | Abnova provides a range of antibodies specific for renal cell carcinomas. | |||
Documents | Cancer | Abnova Corporation | ||
 | Abnova provides a selection of Recombinant Monoclonal Antibodies. | |||
Documents | Antibodies | Abnova Corporation | ||
 | Abnova provides a range of biomarkers specifically for prostate cancer. | |||
Documents | Cancer | Abnova Corporation | ||
 | Abnovas Precipitor™ 32 Plus system is an automated magnetic bead platform for high throughput extraction, purification, and precipitation. Combining 96 deep well plates with conjugated magnetic beads, Precipitor™ 32 Plus easily handles 32 different assays simultaneously by transferring beads from one well to the next for mixing, binding, washing, and elution reactions via the robotic action of parallel magnetic rods. | |||
Documents | Beads | Abnova Corporation | ||
 | Abnova provides antibodies specifically for pancreatic cancer. | |||
Documents | Cancer | Abnova Corporation | ||
 | Abnova provides a range of Non-Small Cell Lung Cancer Antibodies. | |||
Documents | Cancer | Abnova Corporation | ||
 | Abnova has developed numerous DIG-labelled miRNA probes suitable for formalin-fixed, paraffin-embedded (FFPE) tissues, enabling you to assay multiple targets and visualise colocalised signals in specimens. | |||
Documents | miRNA | Abnova Corporation | ||
 | Abnova provides a range of products for Metabolic Regulations in T Cells. | |||
Documents | Immunology | Abnova Corporation | ||
 | General processes for regulating ferroptosis are associated with iron, lipid, and amino acid metabolism. | |||
Documents | Cell Cycle | Abnova Corporation | ||
 | Abnova provides a range of antibodies specifically for melanomas. | |||
Documents | Cancer | Abnova Corporation | ||
 | Abnova provides a range of Macrophage & Dendritic Cell Biomarkers. | |||
Documents | Immunology | Abnova Corporation | ||
 | Abnova provides a range of leukocyte biomarker antibodies. | |||
Documents | Antibodies | Abnova Corporation | ||
 | HIFs induce the expression of integrins. The integrins connect the ECM to the cytoskeleton and form focal adhesion, which enhances the cancer cell motility and invasion capacity. HIFs can also trigger collagen production and regulate the expression of collagen-modifying enzymes. The hypoxia-induced collagen deposition might potentiate cancer metastasis. | |||
Documents | Cancer | Abnova Corporation | ||
 | Infectious disease rapid tests enable the simultaneous detection of multiple markers in serum, plasma, cerebrospinal, and synovial fluid. They are an important tool for the differential study of diseases with similar symptoms. They are used for the confirmation of borderline or positive ELISA. | |||
Documents | Immunology | Abnova Corporation | ||